Literature DB >> 18369399

Agonists and antagonists of metabotropic glutamate receptors: anticonvulsants and antiepileptogenic agents?

Feng Ru Tang1.   

Abstract

Anticonvulsant and neuroprotective effects of agonist and antagonist of metabotropic glutamate receptors (mGluRs) have been known for more than 10 years from multiple studies. However, it is not certain whether these candidate drugs are also antiepileptic and antiepileptogenic, as few studies included the chronic stages to determine whether spontaneous recurrent seizures could be prevented or stopped. Even in the acute stage, differences in experimental design such as timing and route of administration of candidate drugs, age, species and strain of experimental animal and experimental model make it difficult to determine the anticonvulsant and europrotective effects of each candidate drug. This paper, reviews in vivo neuropharmacological studies on agonsists and antagonists of mGluRs in different seizure and epilepsy models in last more than ten years. By combining with our neuropharmacological studies on the effect of mGluR agonists and antagonists in the mouse pilocarpine model of temporal lobe epilepsy, an ideal model for future development of mGluR agonists and antagonists as antiepileptogenic drugs will be proposed.

Entities:  

Year:  2005        PMID: 18369399      PMCID: PMC2268996          DOI: 10.2174/157015905774322525

Source DB:  PubMed          Journal:  Curr Neuropharmacol        ISSN: 1570-159X            Impact factor:   7.363


  76 in total

1.  Influence of SIB 1893, a selective mGluR5 receptor antagonist, on the anticonvulsant activity of conventional antiepileptic drugs in two models of experimental epilepsy.

Authors:  Kinga K Borowicz; Barbara Piskorska; J Łuszczki; Stanisław J Czuczwar
Journal:  Pol J Pharmacol       Date:  2003 Sep-Oct

2.  Temporal lobe epilepsy associated up-regulation of metabotropic glutamate receptors: correlated changes in mGluR1 mRNA and protein expression in experimental animals and human patients.

Authors:  I Blümcke; A J Becker; C Klein; C Scheiwe; A A Lie; H Beck; A Waha; M G Friedl; R Kuhn; P Emson; C Elger; O D Wiestler
Journal:  J Neuropathol Exp Neurol       Date:  2000-01       Impact factor: 3.685

3.  Anticonvulsant activity of a mGlu(4alpha) receptor selective agonist, (1S,3R,4S)-1-aminocyclopentane-1,2,4-tricarboxylic acid.

Authors:  A G Chapman; A Talebi; P K Yip; B S Meldrum
Journal:  Eur J Pharmacol       Date:  2001-07-20       Impact factor: 4.432

4.  Group I mGluR-mediated silent induction of long-lasting epileptiform discharges.

Authors:  L R Merlin
Journal:  J Neurophysiol       Date:  1999-08       Impact factor: 2.714

5.  Decreased sensitivity to Group III mGluR agonists in the lateral perforant path following kindling.

Authors:  G J Klapstein; B S Meldrum; I Mody
Journal:  Neuropharmacology       Date:  1999-07       Impact factor: 5.250

6.  AIDA, a class I metabotropic glutamate-receptor antagonist limits kainate-induced hippocampal dysfunction.

Authors:  Johanne Renaud; Martine Emond; Sébastien Meilleur; Caterina Psarropoulou; Lionel Carmant
Journal:  Epilepsia       Date:  2002-11       Impact factor: 5.864

7.  Expression analysis of metabotropic glutamate receptors I and III in mouse strains with different susceptibility to experimental temporal lobe epilepsy.

Authors:  J Chen; S Larionov; J Pitsch; N Hoerold; C Ullmann; C E Elger; J Schramm; A J Becker
Journal:  Neurosci Lett       Date:  2004-12-10       Impact factor: 3.046

8.  Status epilepticus causes long-term NMDA receptor-dependent behavioral changes and cognitive deficits.

Authors:  A C Rice; C L Floyd; B G Lyeth; R J Hamm; R J DeLorenzo
Journal:  Epilepsia       Date:  1998-11       Impact factor: 5.864

Review 9.  Review: cholinergic mechanisms and epileptogenesis. The seizures induced by pilocarpine: a novel experimental model of intractable epilepsy.

Authors:  L Turski; C Ikonomidou; W A Turski; Z A Bortolotto; E A Cavalheiro
Journal:  Synapse       Date:  1989       Impact factor: 2.562

10.  Status epilepticus in immature rats leads to behavioural and cognitive impairment and epileptogenesis.

Authors:  Hana Kubová; Pavel Mares; Lucie Suchomelová; Gustav Brozek; Rastislav Druga; Asla Pitkänen
Journal:  Eur J Neurosci       Date:  2004-06       Impact factor: 3.386

View more
  6 in total

Review 1.  mGluRs modulate strength and timing of excitatory transmission in hippocampal area CA3.

Authors:  Kathleen E Cosgrove; Emilio J Galván; Germán Barrionuevo; Stephen D Meriney
Journal:  Mol Neurobiol       Date:  2011-05-11       Impact factor: 5.590

2.  High affinity group III mGluRs regulate mossy fiber input to CA3 interneurons.

Authors:  Kathleen E Cosgrove; Stephen D Meriney; Germán Barrionuevo
Journal:  Hippocampus       Date:  2010-09-07       Impact factor: 3.899

3.  Biallelic GRM7 variants cause epilepsy, microcephaly, and cerebral atrophy.

Authors:  Dana Marafi; Tadahiro Mitani; Sedat Isikay; Jozef Hertecant; Mohammed Almannai; Kandamurugu Manickam; Rami Abou Jamra; Ayman W El-Hattab; Jaishen Rajah; Jawid M Fatih; Haowei Du; Ender Karaca; Yavuz Bayram; Jaya Punetha; Jill A Rosenfeld; Shalini N Jhangiani; Eric Boerwinkle; Zeynep C Akdemir; Serkan Erdin; Jill V Hunter; Richard A Gibbs; Davut Pehlivan; Jennifer E Posey; James R Lupski
Journal:  Ann Clin Transl Neurol       Date:  2020-04-14       Impact factor: 4.511

Review 4.  Main path and byways: non-vesicular glutamate release by system xc(-) as an important modifier of glutamatergic neurotransmission.

Authors:  Ann Massie; Séverine Boillée; Sandra Hewett; Lori Knackstedt; Jan Lewerenz
Journal:  J Neurochem       Date:  2015-09-29       Impact factor: 5.372

5.  Therapeutic potential of metabotropic glutamate receptor modulators.

Authors:  N Hovelsø; F Sotty; L P Montezinho; P S Pinheiro; K F Herrik; A Mørk
Journal:  Curr Neuropharmacol       Date:  2012-03       Impact factor: 7.363

Review 6.  Metabotropic Glutamate Receptors and Interacting Proteins in Epileptogenesis.

Authors:  Feng Qian; Feng-Ru Tang
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.